PD-L1 Expression in Premalignant and Malignant Trophoblasts From Gestational Trophoblastic Diseases Is Ubiquitous and Independent of Clinical Outcomes

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

Omid Hamid, Caroline Robert, Adil Daud et al. · New England Journal of Medicine · 2013 · 3.4K citations · Full text

Medicine, Immunology, Oncology +17

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy

Janis M. Taube, Alison Klein, Julie R. Brahmer et al. · Clinical Cancer Research · 2014 · 2.3K citations · Full text

Medicine, Immunology, Oncology +17

Prognostic and predictive factors in breast cancer by immunohistochemical analysis.

D. Craig Allred, Jennet Harvey, Melora D. Berardo et al. · PubMed · 1998 · 2.2K citations

Medicine, Cancer Biology, Oncology +16

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

Caroline Robert, Antoni Ribas, Jedd D. Wolchok et al. · The Lancet · 2014 · 1.8K citations

Pharmacy, Oncology, Pharmacotherapy +17

FIGO staging for gestational trophoblastic neoplasia 2000

International Journal of Gynecology & Obstetrics · 2002 · 404 citations

Medicine, Gynecology, Obstetrics +11